Drug intelligence / Profile preview

Tiaochang Xiaoyan + Shenling Baizhu

Development stage
Preclinical
Lead developer
Guangzhou University of Chinese Medicine
Administration
Oral
01

Overview

Tiaochang Xiaoyan + Shenling Baizhu is a combination of two traditional Chinese medicine (TCM) herbal formulas used primarily for gastrointestinal disorders, especially chronic colitis and diarrhea. - **Tiaochang Xiaoyan tablet (TCXYT)** is derived from the Xianglian pill and contains Radix Astragali seu Hedysari, Radix Linderae, Rhizoma Coptidis, Herba Hedyotis, and Semen Coicis. It has demonstrated anti-inflammatory effects in preclinical models of ulcerative colitis by promoting mucosal repair, reducing pro-inflammatory cytokines (IL-1β and TNF-α), increasing anti-inflammatory cytokines (IL-4 and IL-10), enhancing lysosomal activity in macrophages, and inhibiting the TLR9/MyD88/IRAK signaling pathway[1][2]. - **Shenling Baizhu San (SLBZS)** is a classical formula composed of 10 herbs including Panax ginseng (Ren Shen), Atractylodes macrocephala (Bai Zhu), Poria cocos (Fu Ling), Glycyrrhiza uralensis (Gan Cao), Dolichos lablab (Bai Bian Dou), Dioscorea opposita (Shan Yao), Nelumbo nucifera seed (Lian Zi), Platycodon grandiflorus root (Jie Geng), Amomum villosum fruit (Sha Ren) and Coix lacryma-jobi seed (Yi Yi Ren). It is traditionally used to strengthen spleen function, resolve dampness, stop diarrhea, improve digestion/absorption, boost energy levels (“qi”), and support recovery from chronic digestive issues such as chronic diarrhea or ulcerative colitis[4][5][6][7]. The combination aims to synergistically address both inflammation/injury repair in the colon as well as underlying “spleen deficiency” with dampness according to TCM theory. This dual approach targets both acute symptoms of inflammation/ulceration as well as chronic functional weakness contributing to recurrent disease.

Other names
TCXYT + SLBZSTiaochang Xiaoyan tablet combined with Shenling Baizhu San
02

Targets

MYD88 (Myeloid differentiation primary response protein MyD88)IRAK4 (Interleukin-1 receptor associated kinase 4)TLR9 (Toll-like receptor 9)IRAK1 (Interleukin-1 receptor-associated kinase 1)

Beyond the preview

Go deeper on Tiaochang Xiaoyan + Shenling Baizhu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaochang Xiaoyan + Shenling Baizhu.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call